Polaris Office Forms Strategic Partnership with OpenAI to Enter US AI Healthcare Market

원본보기 아이콘

Polaris Office has signed a strategic partnership with OpenAI and is set to enter the US AI healthcare market.

On the 13th, Polaris Office announced that it had signed a Business Associate Agreement (BAA) with OpenAI. Through this agreement, the company plans to establish a medical data processing environment that meets the standards of HIPAA, the US Health Insurance Portability and Accountability Act, and to actively pursue healthcare solution business utilizing OpenAI-based artificial intelligence technology.

The BAA is a mandatory legal security contract that must be signed when US medical institutions or healthcare companies share patients’ sensitive medical information (PHI) with external companies. With this agreement, Polaris Office has secured a foundation to handle medical and pharmaceutical data safely and without legal risk.

In particular, the company explained that it has met the key requirements for entering the US healthcare market by combining its own AI document analysis technology with OpenAI’s large language model (LLM). Based on this, Polaris Office plans to expand its AI solution business targeting the global healthcare and pharmaceutical industries.

The core solution of this partnership is ‘AskDoc for Pharma,’ an industry-specialized AI service. This solution was jointly developed by combining Polaris Office’s document AI technology with the pharmaceutical and bio industry expertise of its affiliate, Polaris AI Pharma.

‘AskDoc for Pharma’ provides an AI-powered function that automatically analyzes and summarizes large volumes of specialized documents generated during new drug development and clinical trial processes. Its features include quickly sorting complex documents such as clinical trial protocols, US Food and Drug Administration approval documents, and pharmaceutical ingredient analysis reports, and providing accurate answers to researchers’ queries.

Through this, pharmaceutical and bio companies are expected to significantly reduce the time required for research and document review and to improve decision-making efficiency.

A Polaris Office representative stated, “Signing the BAA with OpenAI is more than just a technical collaboration; it means we have been recognized as an AI platform company that meets the United States’ strict medical security standards,” adding, “Having secured a core foundation for entering the global healthcare market, we plan to grow ‘AskDoc for Pharma’ into an intelligent decision-making platform for the pharmaceutical and medical industries.”

Meanwhile, Polaris Group owns a variety of affiliates in diverse industries-including Polaris Office, Polaris Sewon, Polaris Uno, Polaris AI, and Polaris AI Pharma-and is actively implementing its ‘Vertical AI’ strategy to build industry-specialized artificial intelligence. Through this collaboration with OpenAI, the company also plans to accelerate business expansion in the global AI market, including the healthcare and pharmaceutical sectors.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.